Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout
- PMID: 9598031
- DOI: 10.1007/978-1-4615-5381-6_11
Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout
Abstract
We measured the serum concentrations of 1,25(OH)2-vitamin D3, 25(OH)-vitamin D3, parathyroid hormone (PTH) in 82 male patients with primary gout whose serum uric acid was significantly higher than that of 41 normal control male subjects (8.8 +/- 0.2 vs 5.6 +/- 0.2 mg/dL, p < 0.001). The serum 1,25(OH)2-vitamin D3 concentration was significantly lower in the patients with gout compared with the control subjects (39.6 +/- 1.4 vs 44.8 +/- 1.7 pg/mL, p < 0.05), while no differences were observed between the two groups in either the serum concentration of 25(OH)-vitamin D3 or PTH. The administration of uric acid lowering agent to the patients for 1 year caused a significant increase in their serum 1,25(OH)2-vitamin D3 concentration which was associated with a significant decrease in their serum uric acid concentration. In contrast, the serum concentrations of 25(OH)-vitamin D3 and PTH were not affected by these drugs. These results suggest that uric acid per se may directly decrease the serum concentration of 1,25(OH)2-vitamin D3 in patients with gout by inhibiting 1-hydroxylase activity.
Similar articles
-
Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout.Metabolism. 1998 Mar;47(3):336-8. doi: 10.1016/s0026-0495(98)90267-0. Metabolism. 1998. PMID: 9500573
-
Inhibition of xanthine oxidase and exercise on serum uric acid, 25(OH)D3, and calcium concentrations.Clin Lab. 2014;60(8):1409-11. doi: 10.7754/clin.lab.2013.130830. Clin Lab. 2014. PMID: 25185430 Clinical Trial.
-
In colorectal carcinoma patients, serum vitamin D levels vary according to stage of the carcinoma.Cancer. 1999 Aug 1;86(3):391-7. doi: 10.1002/(sici)1097-0142(19990801)86:3<391::aid-cncr5>3.0.co;2-a. Cancer. 1999. PMID: 10430245
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Asymptomatic hyperuricemia: to treat or not to treat.Cleve Clin J Med. 2002 Aug;69(8):594, 597, 600-2 passim. doi: 10.3949/ccjm.69.8.594. Cleve Clin J Med. 2002. PMID: 12184468 Review.
Cited by
-
Metabolomics Coupled with Pathway Analysis Provides Insights into Sarco-Osteoporosis Metabolic Alterations and Estrogen Therapeutic Effects in Mice.Biomolecules. 2021 Dec 28;12(1):41. doi: 10.3390/biom12010041. Biomolecules. 2021. PMID: 35053189 Free PMC article.
-
Calcitriol Treatment Attenuates Uric Acid-Induced Kidney Injury via Super Oxide Dismutase-1 (SOD-1) Upregulation and Fibrosis Reduction.Iran Biomed J. 2021 Nov 1;25(6):417-25. doi: 10.52547/ibj.25.6.417. Iran Biomed J. 2021. PMID: 34641645 Free PMC article.
-
Specific higher levels of serum uric acid might have a protective effect on bone mineral density within a Chinese population over 60 years old: a cross-sectional study from northeast China.Clin Interv Aging. 2019 Jun 12;14:1065-1073. doi: 10.2147/CIA.S186500. eCollection 2019. Clin Interv Aging. 2019. PMID: 31354250 Free PMC article.
-
Gout is associated with elevated risk of erectile dysfunction: a systematic review and meta-analysis.Rheumatol Int. 2019 Sep;39(9):1527-1535. doi: 10.1007/s00296-019-04365-x. Epub 2019 Jul 5. Rheumatol Int. 2019. PMID: 31278432
-
Lower vitamin D levels are associated with depression in patients with gout.Neuropsychiatr Dis Treat. 2019 Jan 14;15:227-231. doi: 10.2147/NDT.S193114. eCollection 2019. Neuropsychiatr Dis Treat. 2019. PMID: 30679908 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical